Pacific Biosciences of California, Inc.

NasdaqGS:PACB Stock Report

Market Cap: US$493.0m

Pacific Biosciences of California Past Earnings Performance

Past criteria checks 0/6

Pacific Biosciences of California's earnings have been declining at an average annual rate of -40.2%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 18.7% per year.

Key information

-40.2%

Earnings growth rate

-30.8%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate18.7%
Return on equity-87.0%
Net Margin-227.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Nov 12

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Nov 07
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Oct 16
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Sep 20
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25
These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Revenue & Expenses Breakdown

How Pacific Biosciences of California makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:PACB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24173-394165146
30 Jun 24189-400172168
31 Mar 24200-297174182
31 Dec 23201-307170187
30 Sep 23170-309169185
30 Jun 23146-319162185
31 Mar 23134-321161189
31 Dec 22128-314161193
30 Sep 22137-299153193
30 Jun 22140-206148173
31 Mar 22135-175138145
31 Dec 21131-181124113
30 Sep 21122-3710588
30 Jun 21106-779477
31 Mar 2192-598069
31 Dec 2079297364
30 Sep 2080-468461
30 Jun 2083-517159
31 Mar 2090-537559
31 Dec 1991-847560
30 Sep 1982-1156262
30 Jun 1979-1116861
31 Mar 1976-1096462
31 Dec 1879-1036363
30 Sep 1884-935862
30 Jun 1889-905863
31 Mar 1888-935965
31 Dec 1793-925965
30 Sep 1794-905866
30 Jun 1796-865668
31 Mar 1797-795168
31 Dec 1691-744868
30 Sep 16101-574866
30 Jun 1690-374665
31 Mar 1694-314662
31 Dec 1593-324560
30 Sep 1573-494258
30 Jun 1580-604154
31 Mar 1567-674051
31 Dec 1461-663848
30 Sep 1453-643747
30 Jun 1440-763846
31 Mar 1434-773845
31 Dec 1328-793945

Quality Earnings: PACB is currently unprofitable.

Growing Profit Margin: PACB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PACB is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.

Accelerating Growth: Unable to compare PACB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PACB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).


Return on Equity

High ROE: PACB has a negative Return on Equity (-87.01%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies